Marc MartinezLlordella

Company: Quell Therapeutics

Job title: Co-Founder & VP Biology

Seminars:

Advancing Treg Cell Therapy with 3 Engineered Genes for Improved Specificity, Stability & Safety 2:00 pm

Explaining the science behind Quell’s approach to building a Treg cell therapy in autoimmunity, inflammation and transplant rejection Reflecting on preclinical data to explain improved antigen specificity and stability model for generating efficacious and safe products Glimpsing at clinical development of Quell’s Treg therapy, from Treg population isolation to expansion, clinical design and clinical outcomes…Read more

day: Day One | Track A | Morning